High materiality7/10
Kazia Therapeutics initiated with a Buy at Canaccord
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Kazia Therapeutics received a Buy rating from Canaccord Genuity with a target of $29. The stock's price at the signal was $12.79, and the target update came alongside a price move of +5.71 since the signal.
- Kazia: Canaccord Buy; target 29; price 12.79; +5.71 since signal.
Key facts
- 01
Target: $29
- 02
Posted price: $12.79
- 03
Analyst firm: Canaccord Genuity
- 04
Analyst: John Newman
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.